menu
    • menu
    [{"orgOrder":0,"company":"Cellerys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"CLS12311","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Cellerys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellerys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Cellerys \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Cellerys","sponsor":"Novartis Pharmaceuticals Corporation | Scope International AG | Tetec AG | Jung Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CLS12311","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cellerys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellerys \/ Novartis Pharmaceuticals Corporation | Scope International AG | Tetec AG | Jung Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Cellerys \/ Novartis Pharmaceuticals Corporation | Scope International AG | Tetec AG | Jung Diagnostics"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellerys

    Menu

    Cellerys

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cellerys

                            Switzerland arrow
                            ESCRS
                            Not Confirmed

                            Cellerys

                            Switzerland arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLS12311

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Novartis Pharmaceuticals Corporation | Scope International AG | Tetec AG | Jung Diagnostics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : CLS12311

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Novartis Pharmaceuticals Corporation | Scope International AG | Tetec AG | Jung Diagnostics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cellerys

                            Switzerland arrow
                            ESCRS
                            Not Confirmed

                            Cellerys

                            Switzerland arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLS12311

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Novartis Signs Deal that Could Lead to Acquisition of Zurich Start-Up Cellerys

                            Details : Zurich-based Cellerys is working on new multiple sclerosis drug, CLS12311, which is currently in phase 2. Novartis is pairing up with the biotech on the asset but nabs the option to acquire Cellerys upon completion of a phase 2 trial in the coming years.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 06, 2021

                            Lead Product(s) : CLS12311

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth